Award
National Institute of General Medical Sciences 5R16GM149412-04
Inhibitors of Human Factor XIIIa as New Anticoagulants
Recipient
Xavier University of Louisiana
Award Amount
$150,000.00
Ceiling
$150,000.00
Awarded
April 10, 2026
Identifier
5R16GM149412-04
This award funds research to develop new anticoagulants targeting human factor XIIIa to prevent venous thromboembolism with reduced bleeding risk, by synthesizing and testing novel inhibitors.
Description
The project aims at developing effective and safer anticoagulants by targeting human factor XIIIa (FXIIIa) to protect against venous thromboembolism (VTE) without causing significant bleeding. The research involves synthesizing libraries of lead molecules that inhibit FXIIIa and evaluating their potential as anticoagulants using a multidisciplinary approach. The innovation lies in targeting FXIIIa allosterically, which could lead to safer anticoagulant therapies with reduced bleeding risk.